Navigation Links
Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA,Nanoparticles

CLEVELAND--(BUSINESS WIRE)--Jun 4, 2007 - Copernicus Therapeutics, Inc. announced today that a research team at University of Oklahoma Health Sciences Center, led by Dr. Muna Naash, Professor of Cell Biology, demonstrated that Copernicus' DNA nanoparticles corrected vision defects in a mouse model of retinitis pigmentosa (RP). These findings were presented at the American Society of Gene Therapy meeting in Seattle, WA. Mutations in genes important in the biology of vision cause RP, a common genetic form of visual impairment affecting nearly 70,000 patients in the United States.

"These exciting results demonstrate that delivery of normal copies of genes into photoreceptor cells can correct vision defects in RP," said Mark Cooper, M.D., Senior Vice President of Science and Medical Affairs. "In addition to the promise of providing corrective therapy for genetic diseases such as retinitis pigmentosa, nucleic acid nanoparticles may also offer the potential to provide effective treatments for more complex disorders such as diabetic retinopathy, macular degeneration, and various diseases that injure ganglion cells and the optic nerve."

"We are pleased by the promise of these results and look forward to moving these studies forward to a potential human clinical trial," said Dr. Naash.

"Gene therapy holds great potential for treating and possibly curing a variety of vision-robbing retinal degenerative diseases," says Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness. "Dr. Naash and Copernicus are demonstrating that nanoparticles show excellent potential for safely and effectively delivering therapeutic genes to the retina." Dr. Naash's work was funded in part by the Foundation Fighting Blindness.

About Copernicus, the University of Oklahoma and the Foundation Fighting Blindness

Copernicus Therapeutics, Inc., a privately held biotechnology company, is dedicated to deli vering the promise of nucleic acid therapeutics. The same technology that is being tested for its ability to deliver corrective nucleic acids for various blinding disorders is being developed for introducing the cystic fibrosis gene to the lungs of CF patients. The Copernicus multi-component delivery platform can be used to develop nucleic acid therapies for numerous human diseases. Additional information about Copernicus is available at www.cgsys.com.

The University of Oklahoma is a doctoral degree-granting research university serving the educational, cultural, economic and health care needs of the state, region and nation. The OU Health Sciences Center, which is located in Oklahoma City, is one of only four comprehensive academic health centers in the nation with seven professional colleges. Additional information about University of Oklahoma Health Sciences Center is available at www.ouhsc.edu.

The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa (RP), macular degeneration, Usher syndrome, and the entire spectrum of retinal degenerative diseases. Visit www.FightBlindness.org for more information on the Foundation's efforts.

Contact

Copernicus Therapeutics, Inc.
Robert C. Moen, M.D., Ph.D., 216-231-0227 x26
President & CEO
or
Mark J. Cooper, M.D., 216-231-0227 x23
Sr. V.P. of Science and Medical Affairs
OR
University of Oklahoma
Catherine F. Bishop, 405-325-1543
Vice President Public Affairs
OR
Foundation Fighting Blindness
David Harrison, 410-804-1728
Media Contact


'"/>




Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Advanced Cell Technologys Ability to Rescue Vision in Blind Rats Noted in Scientific American
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):